The FDA has granted regular approval to capmatinib (Tabrecta®, Novartis Pharmaceuticals Corp.) for treatment of adult patients with metastatic non–small cell lung cancer (NSCLC) who have tumors evolving into the mesenchymal-epithelial transition exon 14 skipping (METex14) mutation. Capmatinib was previously granted accelerated approval in May 2020 based on initial data from the GEOMETRY mono-1 trial (NCT02414139); due to updated results, the FDA is now converting it to regular approval. "Activat...
Oncology Data Advisor™ · Diagnosis and Evidence-Based Management of T-Cell Lymphoma T-cell lymphoma (TCL) is an uncommon subtype accounting for approximately 15% of all cases of non-Hodgkin lymphoma in the United States (LRF, 2022). Compared with its B-cell counterpart, TCL has a poor prognosis and is associated with a 5-year survival rate of less than 20%. The clinical and pathologic presentations of TCL are varied and often nonspecific, making diagnosis and treatment challenging (...
The FDA has approved darolutamide (Nubeqa®, Bayer HealthCare Pharmaceuticals Inc.) in combination with docetaxel for adult patients with metastatic hormone-sensitive prostate cancer (mHSPC). "Standard treatment for patients with metastatic, hormone-sensitive prostate cancer includes the addition of either docetaxel or an androgen-receptor pathway inhibitor to androgen-deprivation therapy," wrote Matthew Smith, MD, PhD, Director of the Genitourinary Malignancies Program at the Massachusetts Gener...
The FDA has approved fam-trastuzumab deruxtecan-nxki (Enhertu®, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)–low breast cancer. This treatment is indicated for patients who have previously undergone chemotherapy in the metastatic setting or who developed disease recurrence during or within six months of completing adjuvant chemotherapy. "Currently available HER2-directed therapies have not improved clinical outcomes in p...
At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, Dr. Ash Alpert, a postdoctoral fellow in health services research at Brown University, presented two posters regarding the associations between violence and cancer risk factors for transgender and cisgender people. In this follow-up interview with Oncology Data Advisor, Dr. Alpert delves further into the implications of these two studies' results and shares how their ongoing research in this field seeks to improve the care of transgender people in the health care setting.
It's been a busy three months here at Oncology Data Advisor (ODA) since I last banged out an "Editor's Notes." One of the highlights was ODA's presence at the American Society of Clinical Oncology (ASCO) Annual Meeting. Many researchers spoke on camera with us about the work they were presenting at the meeting, and visibility for the website increased tremendously. It was a rousing success. I remain incredibly proud of all the hard work our staff does every day to bring the cutting edge of clini...
On August 1st, Oncology Data Advisor hosted a live panel discussion in honor of World Lung Cancer Day, featuring Beth Sandy, MSN, CRNP, and Corey Langer, MD, both of the University of Pennsylvania Abramson Cancer Center. Ms. Sandy and Dr. Langer discussed the improvements in survival that have occurred in recent years due to the development of novel therapies, groundbreaking developments in the fields of immunotherapy and targeted therapy, and exciting advances that lay on the horizon for patients with lung cancer in the coming years.
An educational enduring online activity provided by i3 Health has demonstrated knowledge gains regarding the best treatment and management of advanced soft tissue sarcoma. Soft tissue sarcomas are a heterogeneous group of malignancies that arise primarily from the mesodermal tissues of the extremities, trunk and retroperitoneum, and head and neck. The American Cancer Society estimated that 13,190 new cases will be diagnosed in the United States in 2022, and 5,130 of these cases are estimated to ...
Chemotherapy-induced neutropenia (CIN) is a common and potentially life-threatening consequence of chemotherapy, as it may lead to serious infections for patients with cancer. These infections result in hospital stays, increased morbidity and mortality, and considerable financial burden. In this interview, Dr. Maura Abbott explains the importance of managing and educating patients about CIN.
At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Colin Ferro, Director of Operations at Epic Experience, spoke with Oncology Data Advisor about the organization's mission to empower adult cancer survivors and thrivers beyond their diagnosis and treatment.
This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed.
Oncology Data Advisor™ · Treatment Advances in Waldenstrom Macroglobulinemia Waldenstrom macroglobulinemia (WM) is a rare cancer of B lymphocytes associated with lymphoplasmacytic bone marrow infiltration and the presence of serum monoclonal immunoglobulin M (IgM) (LLS, 2021). Often considered a disease occurring in older adults, this malignancy accounts for between 1% and 2% of non-Hodgkin lymphomas (Dimopoulos & Kastritis, 2019; ACS, 2018).&n...
At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Ian Krop, Director of the Yale Cancer Center Clinical Trials Office, sat down with Oncology Data Advisor to discuss his research and the data he presented regarding the HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) for treatment of metastatic breast cancer.
This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMED.
A learning opportunity provided by i3 Health has demonstrated significant knowledge gains regarding the latest advances in the treatment of myelodysplastic syndromes. These findings were presented at the 4th Annual Greater Los Angeles Oncology Nursing Society (GLAONS) Oncology Care Summit.
At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Wendy London, Associate Professor of Pediatrics at Harvard Medical School, sat down with Oncology Data Advisor to share her research regarding risk stratification, reduction of therapy, and survival outcomes for pediatric patients with neuroblastoma.
This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed.
At the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Dr. Jeanne Tie spoke with Oncology Data Advisor to share more about her presentation regarding the clinical utility of circulating tumor DNA (ctDNA) analysis to guide treatment decision making for patients with colorectal cancer.
At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Jessica Jones, Assistant Professor of Oncology at the University of Texas (UT) Health System, sat down with Oncology Data Advisor to discuss her work in cancer detection and cancer prevention in Black women with a higher risk of developing breast cancer and bridging the racial gap in breast cancer morbidity and mortality with early detection and prevention.
This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed.
Oncology Data Advisor™ · Updates in Mantle Cell Lymphoma Mantle cell lymphoma (MCL) is an aggressive variant of B-cell non-Hodgkin lymphoma that comprises approximately 5% of all lymphomas. Compared with patients who have other aggressive lymphomas, patients with MCL often do not respond as well to treatment (ACS, 2019).Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall sur...
At the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Alexander Spira, MD, PhD, FACP, Director of the Thoracic and Phase I Program at the Virginia Cancer Specialists, the US Oncology Network, met with Oncology Data Advisor to discuss his presentation about adagrasib for KRAS G12–mutated non–small cell lung cancer with active central nervous system (CNS) metastases.
At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Dr. Jason Mouabbi of MD Anderson Cancer Center presented a poster focused on survival outcomes of patients with invasive lobular carcinoma treated with endocrine therapy plus a CDK4/6 inhibitor, mammalian target of rapamycin (mTOR) inhibitor, or a PI3K inhibitor, in comparison to those with metastatic hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative invasive ductal carcinoma. Afterwards, he sat down with Oncology Data Advisor to explain the implication of the study's results and the need for additional research in the field of lobular breast cancer to improve patient outcomes.
This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed.
Following the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Cherry Au, MD, of Rush University Medical Center, spoke with Oncology Data Advisor to discuss her abstract, Medical Student Clinical Cultural Awareness in Cancer Care of Sexual and Gender Minorities.